Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Maria Frezza

Showing results (11-20 of 70) with videos related to

Pageof 7
Sort By:
Current Opinion in Oncology|December 27, 2018
Chordoma: update on disease, epidemiology, biology and medical therapiesAnna Maria Frezza, Laura Botta, Annalisa Trama, et al.
Surgical Oncology Clinics of North America|June 17, 2022
Management of Vascular SarcomaAparna Subramaniam, Claudia Giani, Andrea Napolitano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 14, 2011
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimenBruno Vincenzi, Santini Daniele, Anna Maria Frezza, et al.
Expert Opinion on Drug Safety|March 17, 2011
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimenBruno Vincenzi, Daniele Santini, Anna Maria Frezza, et al.
Expert Opinion on Therapeutic Targets|March 1, 2013
Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimensDaniele Santini, Anna Maria Frezza, Olga Venditti, et al.
Expert Opinion on Investigational Drugs|October 21, 2011
Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedsideBruno Vincenzi, Andrea Napolitano, Loretta D'Onofrio, et al.
BMC Cancer|January 16, 2014
Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?Anna Maria Frezza, Tim Beale, Jamshed Bomanji, et al.
Critical Reviews in Oncology/Hematology|December 25, 2015
Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trialsSalvatore Galdy, Chiara Alessandra Cella, Francesca Spada, et al.
BMC Research Notes|April 19, 2015
Classic Kaposi Sarcoma: to treat or not to treat?Bruno Vincenzi, Loretta D'Onofrio, Anna Maria Frezza, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 1, 2012
Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IVBruno Vincenzi, Anna Maria Frezza, Gaia Schiavon, et al.
Pageof 7

Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Current Opinion in Oncology|December 27, 2018
Chordoma: update on disease, epidemiology, biology and medical therapiesAnna Maria Frezza, Laura Botta, Annalisa Trama, et al.
Surgical Oncology Clinics of North America|June 17, 2022
Management of Vascular SarcomaAparna Subramaniam, Claudia Giani, Andrea Napolitano, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 14, 2011
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimenBruno Vincenzi, Santini Daniele, Anna Maria Frezza, et al.
Expert Opinion on Drug Safety|March 17, 2011
The role of S-adenosyl methionine in preventing FOLFOX-induced liver toxicity: a retrospective analysis in patients affected by resected colorectal cancer treated with adjuvant FOLFOX regimenBruno Vincenzi, Daniele Santini, Anna Maria Frezza, et al.
Expert Opinion on Therapeutic Targets|March 1, 2013
Comment and reply on: pegfilgrastim is safe and effective in the prevention of neutropenia and treatment delays in biweekly regimensDaniele Santini, Anna Maria Frezza, Olga Venditti, et al.
Expert Opinion on Investigational Drugs|October 21, 2011
Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedsideBruno Vincenzi, Andrea Napolitano, Loretta D'Onofrio, et al.
BMC Cancer|January 16, 2014
Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?Anna Maria Frezza, Tim Beale, Jamshed Bomanji, et al.
Critical Reviews in Oncology/Hematology|December 25, 2015
Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trialsSalvatore Galdy, Chiara Alessandra Cella, Francesca Spada, et al.
BMC Research Notes|April 19, 2015
Classic Kaposi Sarcoma: to treat or not to treat?Bruno Vincenzi, Loretta D'Onofrio, Anna Maria Frezza, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|December 1, 2012
Identification of clinical predictive factors of oxaliplatin-induced chronic peripheral neuropathy in colorectal cancer patients treated with adjuvant Folfox IVBruno Vincenzi, Anna Maria Frezza, Gaia Schiavon, et al.
Pageof 7